Search results
Analog Devices CEO Vincent Roche sells $2.35 million in stock By Investing.com
Investing.com· 3 days agoThe sale was executed under a 10b5-1 trading plan, which was adopted by Roche on March 1, 2024. In...
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
Zacks via Yahoo Finance· 3 days agoWe believe all these factors should keep the stock afloat this year. Zacks Rank Teva currently has a...
Amid surging tech stocks and salaries, HubSpot CEO doubled her pay to $26 million last year - The...
The Boston Globe· 3 days agoAfter a strong year for technology stock returns, tech company leaders around Boston saw their total...
Halozyme's (HALO) ENHANZE Product Gets New Patent Grant in EU
Zacks via Yahoo Finance· 20 hours agoHalozyme (HALO) is set to benefit from the new patent grant in the EU, ensuring the protection of...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 7 days agoIn the first quarter, Halozyme earned an adjusted 79 cents per share on $196 million in sales, up a...
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors
Motley Fool via Yahoo Finance· 6 days agoThe Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. *Stock Advisor...
Is Biogen Inc (BIIB) Set to Underperform? Analyzing the Factors
Guru Focus· 7 days agoLong-established in the Drug Manufacturers industry, Biogen Inc (BIIB, Financial) has enjoyed a stellar reputation. Notably, its diminished rankings in financial strength, growth, and valuation ...
Inari's (NARI) Expanding Product Portfolio Offsets Competition
Zacks· 3 days agoThe adoption of these products is rising on the back of their features, including minimally invasive, novel, catheter-based mechanical thrombectomy devices and their accessories to address the ...
Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study
Zacks via Yahoo Finance· 3 days agoAffimed (AFMD) rallies 69% on positive follow-up efficacy data from its early to mid-stage study of...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 7 days agoAstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as...